- Home
- INTU vs REGN Comparison
INTU vs REGN Comparison
Compare INTU & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | REGN |
|---|---|---|
| Founded | 1983 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.6B | 68.8B |
| IPO Year | 1996 | 1995 |
Fundamental Metrics
Financial Performance| Metric | INTU | REGN |
|---|---|---|
| Price | $316.07 | $762.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 25 |
| Target Price | $692.35 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 3.9M | 742.6K |
| Earning Date | 05-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.22% | 0.55% |
| EPS Growth | ★ 31.06 | 8.19 |
| EPS | 15.05 | ★ 18.95 |
| Revenue | ★ $18,831,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $15.03 | $12.45 |
| Revenue Next Year | $12.41 | $10.13 |
| P/E Ratio | ★ $20.91 | $38.94 |
| Revenue Growth | 15.63 | ★ 20.82 |
| 52 Week Low | $252.84 | $541.00 |
| 52 Week High | $794.09 | $821.11 |
Technical Indicators
Market Signals| Indicator | INTU | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 74.63 |
| Support Level | $300.50 | $732.04 |
| Resistance Level | $420.38 | $783.87 |
| Average True Range (ATR) | 14.28 | 19.21 |
| MACD | 5.05 | 7.44 |
| Stochastic Oscillator | 64.93 | 92.79 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.